GlassScriptPhysician profile
Khalid R Zarug
NPI 1629381447
$7,569.92
in general payments reported to CMS, 2019-2025
40 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $607 · 2021: $788 · 2022: $761 · 2023: $1,843 · 2024: $1,443 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,715.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,092.28 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $794.62 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Dexcom, INC. | $634.84 | 2019-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Amgen INC. | $617.44 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $608.87 | 2019-2024 | Freestyle Libre 3 |
| Insulet Corporation | $547.89 | 2020-2025 | Omnipod |
| Medtronic, INC. | $521.34 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.61 | 2019-2025 | Jardiance |
| Abbvie INC. | $295.81 | 2020-2025 | Synthroid |
| Corcept Therapeutics | $272.25 | 2019-2025 | Korlym |
| Tandem Diabetes Care, INC. | $195.45 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Recordati_rare_diseases_inc. | $187.25 | 2020-2025 | Isturisa |
| Mannkind Corporation | $164.96 | 2019-2021 | |
| Antares Pharma, INC. | $152.62 | 2019-2023 | Nocdurna, Tlando, Xyosted |
| Sanofi-Aventis U.S. LLC | $121.96 | 2019-2024 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khalid Zarug listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.